Do analysts recommend HSCS or PTHL?

HeartSciences currently has a consensus price target of $8.00, suggesting a potential upside of 234.73%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, HSCS or PTHL?

Pheton has higher revenue and earnings than HeartSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences N/A N/A -$8.77M -$3.94 N/A Pheton $305.22K 5.71 -$660K N/A N/A

Is HSCS or PTHL more profitable?

Pheton's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -275.02% -137.21% Pheton N/A N/A N/A

Does the media prefer HSCS or PTHL?

In the previous week, HeartSciences had 4 more articles in the media than Pheton. MarketBeat recorded 5 mentions for HeartSciences and 1 mentions for Pheton. Pheton's average media sentiment score of 0.00 beat HeartSciences' score of -0.03 indicating that Pheton is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pheton 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PTHL or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, PTHL or MBAI?

Check-Cap has lower revenue, but higher earnings than Pheton. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 5.71 -$660K N/A N/A Check-Cap N/A N/A $4.14M -$2.01 N/A

Is PTHL or MBAI more profitable?

Company Net Margins Return on Equity Return on Assets Pheton N/A N/A N/A Check-Cap N/A N/A N/A

Does the media favor PTHL or MBAI?

In the previous week, Check-Cap had 1 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Check-Cap and 1 mentions for Pheton. Check-Cap's average media sentiment score of 1.16 beat Pheton's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pheton 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PTHL or NVNO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has stronger earnings and valuation, PTHL or NVNO?

Pheton has higher revenue and earnings than enVVeno Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 5.71 -$660K N/A N/A enVVeno Medical N/A N/A -$19.47M -$25.54 N/A

Is PTHL or NVNO more profitable?

Pheton's return on equity of 0.00% beat enVVeno Medical's return on equity. Company Net Margins Return on Equity Return on Assets Pheton N/A N/A N/A enVVeno Medical N/A -66.39% -60.42%

Do analysts recommend NDRA or PTHL?

ENDRA Life Sciences currently has a consensus target price of $25.00, suggesting a potential upside of 414.40%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NDRA or PTHL?

Pheton has higher revenue and earnings than ENDRA Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A Pheton $305.22K 5.71 -$660K N/A N/A

Is NDRA or PTHL more profitable?

Pheton's return on equity of 0.00% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -433.64% -204.58% Pheton N/A N/A N/A

Does the media favor NDRA or PTHL?

In the previous week, ENDRA Life Sciences had 2 more articles in the media than Pheton. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 1 mentions for Pheton. ENDRA Life Sciences' average media sentiment score of 0.96 beat Pheton's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ENDRA Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pheton 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SINT or PTHL?

Sintx Technologies presently has a consensus target price of $9.33, suggesting a potential upside of 566.67%. Given Sintx Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Sintx Technologies is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, SINT or PTHL?

Pheton has lower revenue, but higher earnings than Sintx Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sintx Technologies $1.02M 5.93 -$10.36M -$5.07 N/A Pheton $305.22K 5.71 -$660K N/A N/A

Does the media refer more to SINT or PTHL?

In the previous week, Sintx Technologies had 1 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Sintx Technologies and 1 mentions for Pheton. Sintx Technologies' average media sentiment score of 1.53 beat Pheton's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sintx Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pheton 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pheton (PTHL) Competitors

$0.26 -0.02 (-5.36%)

As of 07/24/2026

Compare

PTHL vs. HSCS, MBAI, NVNO, NDRA, and SINT

Should you buy Pheton stock or one of its competitors? MarketBeat compares Pheton with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pheton include HeartSciences (HSCS), Check-Cap (MBAI), enVVeno Medical (NVNO), ENDRA Life Sciences (NDRA), and Sintx Technologies (SINT). These companies are all part of the "medical equipment" industry.

How does Pheton compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Pheton's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-275.02%	-137.21%
Pheton	N/A	N/A	N/A

HeartSciences currently has a consensus price target of $8.00, suggesting a potential upside of 234.73%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has higher revenue and earnings than HeartSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$8.77M	-$3.94	N/A
Pheton	$305.22K	5.71	-$660K	N/A	N/A

In the previous week, HeartSciences had 4 more articles in the media than Pheton. MarketBeat recorded 5 mentions for HeartSciences and 1 mentions for Pheton. Pheton's average media sentiment score of 0.00 beat HeartSciences' score of -0.03 indicating that Pheton is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pheton	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Pheton has a beta of 5.4, suggesting that its stock price is 440% more volatile than the broader market.

17.2% of HeartSciences shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

HeartSciences and Pheton tied by winning 6 of the 12 factors compared between the two stocks.

How does Pheton compare to Check-Cap?

Pheton (NASDAQ:PTHL) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Check-Cap has lower revenue, but higher earnings than Pheton.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	5.71	-$660K	N/A	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.01	N/A

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Check-Cap	N/A	N/A	N/A

1.1% of Check-Cap shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Check-Cap had 1 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Check-Cap and 1 mentions for Pheton. Check-Cap's average media sentiment score of 1.16 beat Pheton's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pheton	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Check-Cap beats Pheton on 5 of the 7 factors compared between the two stocks.

How does Pheton compare to enVVeno Medical?

Pheton (NASDAQ:PTHL) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Pheton has higher revenue and earnings than enVVeno Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	5.71	-$660K	N/A	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$25.54	N/A

Pheton's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
enVVeno Medical	N/A	-66.39%	-60.42%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Pheton and Pheton both had 1 articles in the media. enVVeno Medical's average media sentiment score of 1.89 beat Pheton's score of 0.00 indicating that enVVeno Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Pheton	Neutral
enVVeno Medical	Very Positive

34.7% of enVVeno Medical shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pheton and enVVeno Medical tied by winning 5 of the 10 factors compared between the two stocks.

How does Pheton compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Pheton's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Pheton	N/A	N/A	N/A

ENDRA Life Sciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the broader market.

1.2% of ENDRA Life Sciences shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pheton has higher revenue and earnings than ENDRA Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Pheton	$305.22K	5.71	-$660K	N/A	N/A

In the previous week, ENDRA Life Sciences had 2 more articles in the media than Pheton. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 1 mentions for Pheton. ENDRA Life Sciences' average media sentiment score of 0.96 beat Pheton's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pheton	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ENDRA Life Sciences currently has a consensus target price of $25.00, suggesting a potential upside of 414.40%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ENDRA Life Sciences beats Pheton on 7 of the 12 factors compared between the two stocks.

How does Pheton compare to Sintx Technologies?

Sintx Technologies (NASDAQ:SINT) and Pheton (NASDAQ:PTHL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Pheton has a net margin of 0.00% compared to Sintx Technologies' net margin of -1,058.60%. Pheton's return on equity of 0.00% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
Pheton	N/A	N/A	N/A

18.4% of Sintx Technologies shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sintx Technologies presently has a consensus target price of $9.33, suggesting a potential upside of 566.67%. Given Sintx Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Sintx Technologies is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Sintx Technologies had 1 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Sintx Technologies and 1 mentions for Pheton. Sintx Technologies' average media sentiment score of 1.53 beat Pheton's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sintx Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pheton	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pheton has lower revenue, but higher earnings than Sintx Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	5.93	-$10.36M	-$5.07	N/A
Pheton	$305.22K	5.71	-$660K	N/A	N/A

Sintx Technologies has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, meaning that its share price is 440% more volatile than the broader market.

Summary

Sintx Technologies beats Pheton on 9 of the 14 factors compared between the two stocks.

Get Pheton News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTHL vs. The Competition

Export

Metric	Pheton	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.74M	$9.50B	$6.93B	$12.20B
Dividend Yield	N/A	1.62%	2.67%	9.41%
P/E Ratio	N/A	20.62	22.28	21.32
Price / Sales	5.71	19.19	523.79	89.73
Price / Cash	N/A	141.08	49.81	58.78
Price / Book	0.28	6.11	10.28	6.01
Net Income	-$660K	$179.69M	$3.60B	$331.99M
7 Day Performance	-6.13%	-3.06%	-1.27%	-0.63%
1 Month Performance	-18.56%	0.49%	-0.37%	-2.00%
1 Year Performance	-99.09%	9.52%	18.30%	13.62%

Pheton Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTHL Pheton	N/A	$0.27 -5.4%	N/A	-99.0%	$1.74M	$305.22K	N/A	11
HSCS HeartSciences	2.5571 of 5 stars	$2.56 -2.3%	$8.00 +212.5%	-39.2%	$8.34M	N/A	N/A	10	News Coverage Earnings Report Short Interest Decrease
MBAI Check-Cap	0.781 of 5 stars	$1.01 -10.6%	N/A	N/A	$8.24M	N/A	N/A	80	News Coverage Analyst Forecast
NVNO enVVeno Medical	1.6958 of 5 stars	$10.76 -1.3%	N/A	-94.1%	$7.28M	N/A	N/A	30	Upcoming Earnings
NDRA ENDRA Life Sciences	3.1726 of 5 stars	$5.61 +1.3%	$25.00 +345.6%	-26.0%	$7.04M	N/A	N/A	20	Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTHL) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pheton (PTHL) Competitors

PTHL vs. HSCS, MBAI, NVNO, NDRA, and SINT

How does Pheton compare to HeartSciences?

Summary

How does Pheton compare to Check-Cap?

Summary

How does Pheton compare to enVVeno Medical?

Summary

How does Pheton compare to ENDRA Life Sciences?

Summary

How does Pheton compare to Sintx Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pheton (PTHL) Competitors

PTHL vs. HSCS, MBAI, NVNO, NDRA, and SINT

How does Pheton compare to HeartSciences?

Is HSCS or PTHL more profitable?

Do analysts recommend HSCS or PTHL?

Which has stronger earnings & valuation, HSCS or PTHL?

Does the media prefer HSCS or PTHL?

Which has more volatility and risk, HSCS or PTHL?

Do institutionals & insiders have more ownership in HSCS or PTHL?

Summary

How does Pheton compare to Check-Cap?

Which has preferable valuation & earnings, PTHL or MBAI?

Is PTHL or MBAI more profitable?

Do insiders and institutionals have more ownership in PTHL or MBAI?

Does the media favor PTHL or MBAI?

Which has more risk & volatility, PTHL or MBAI?

Do analysts rate PTHL or MBAI?

Summary

How does Pheton compare to enVVeno Medical?

Which has more volatility & risk, PTHL or NVNO?

Which has stronger earnings and valuation, PTHL or NVNO?

Is PTHL or NVNO more profitable?

Do analysts rate PTHL or NVNO?

Does the media favor PTHL or NVNO?

Do institutionals & insiders have more ownership in PTHL or NVNO?

Summary

How does Pheton compare to ENDRA Life Sciences?

Is NDRA or PTHL more profitable?

Which has more risk & volatility, NDRA or PTHL?

Do insiders & institutionals believe in NDRA or PTHL?

Which has better earnings and valuation, NDRA or PTHL?

Does the media favor NDRA or PTHL?

Do analysts recommend NDRA or PTHL?

Summary

How does Pheton compare to Sintx Technologies?

Is SINT or PTHL more profitable?

Do institutionals and insiders believe in SINT or PTHL?

Do analysts prefer SINT or PTHL?

Does the media refer more to SINT or PTHL?

Which has higher valuation and earnings, SINT or PTHL?

Which has more volatility & risk, SINT or PTHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools